Trials / Completed
CompletedNCT01283074
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)
Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 107 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational, multi-center, open-label study will evaluate the prognostic factors of long-term-response and the safety of Pegasys (peginterferon alfa-2a) in patients with HbeAg-negative chronic hepatitis B. Data will be collected for 96 weeks.
Conditions
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2011-01-25
- Last updated
- 2016-11-02
Locations
16 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT01283074. Inclusion in this directory is not an endorsement.